efmoroctocog alfa

DRUG2 trials

Sponsors

Swedish Orphan Biovitrum, AryoGen Pharmed Co.

Conditions

HemophiliaHemophilia A

Unknown Phase

Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

CompletedNCT02976753

Swedish Orphan BiovitrumHemophilia A

Start: 2016-12-31End: 2021-11-03Updated: 2024-10-02

Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study

Not yet recruitingNCT07791836

AryoGen Pharmed Co.Hemophilia A, Hemophilia

Start: 2026-08-23End: 2027-02-20Target: 262Updated: 2026-08-28

Related Papers

Post-Hoc Analyses of A-SURE and PREVENT Confirm the Effectiveness of rFVIIIFc Prophylaxis Across All Ages, BMIs, Severities and Inhibitor Histories

TH Open2026-06-16

A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A

Hematology2025-07-04

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study

BMJ Open2019-05-0110 citations